MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 531227 | Name: Nicaraven
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nicaraven is a hydroxyl radical scavenger with antivasospastic and neuroprotective effects.

Chemical Structure

Nicaraven
Nicaraven
CAS#79455-30-4 (free base)

Theoretical Analysis

MedKoo Cat#: 531227

Name: Nicaraven

CAS#: 79455-30-4 (free base)

Chemical Formula: C15H16N4O2

Exact Mass: 284.1273

Molecular Weight: 284.32

Elemental Analysis: C, 63.37; H, 5.67; N, 19.71; O, 11.25

Price and Availability

Size Price Availability Quantity
100mg USD 650.00 2 Weeks
200mg USD 1,050.00 2 Weeks
500mg USD 1,950.00 2 Weeks
1g USD 2,850.00 2 Weeks
2g USD 4,250.00 2 Weeks
5g USD 6,250.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
79455-30-4 (free base) 1158520-62-7 (2HCl)
Synonym
Nicaraven
IUPAC/Chemical Name
N,N'-(propane-1,2-diyl)dinicotinamide
InChi Key
KTXBOOWDLPUROC-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H16N4O2/c1-11(19-15(21)13-5-3-7-17-10-13)8-18-14(20)12-4-2-6-16-9-12/h2-7,9-11H,8H2,1H3,(H,18,20)(H,19,21)
SMILES Code
CC(NC(C1=CC=CN=C1)=O)CNC(C2=CC=CN=C2)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Nicaraven is a novel chemically synthesized hydroxyl radical-specific scavenger.
In vitro activity:
The antiplatelet activities in vitro of nicaraven were examined. The concentrations of nicaraven tested were 3.50 x 10(-5) mol/L, 1.75 x 10(-4) mol/L, 3.50 x 10(-4) mol/L, and 1.75 x 10(-3) mol/L, respectively. The maximum aggregation rate induced by adenosine diphosphate (ADP) was significantly inhibited by nicaraven at concentration ranges of 3.50 x 10(-4) mol/L or higher in the healthy volunteer platelets. Reference: Clin Neuropharmacol. 1999 Jan-Feb;22(1):11-4. https://pubmed.ncbi.nlm.nih.gov/10047928/
In vivo activity:
Eighteen beagle dogs were randomly assigned to 2 groups: 12 animals were not treated (group I) and 6 were treated with nicaraven (group II). Nicaraven was administered intravenously (2mg/kg/min) for 60 minutes before ischemia and for 3 hours, starting 30 minutes before reperfusion. Two-week survival rates were 25% in group I and 100% in group II (P <.01). Nicaraven inhibited lipid peroxidation in the liver, improved hepatic and systemic hemodynamics and energy metabolism, and suppressed liver enzyme release, endothelin-1 elevation in hepatic venous blood, histologic damage, and neutrophil infiltration into the liver. Reference: Surgery. 2000 Jun;127(6):661-9. https://pubmed.ncbi.nlm.nih.gov/10840362/
Solvent mg/mL mM comments
Solubility
DMF 5.0 17.59
DMSO 55.0 193.44
Ethanol 2.0 7.03
PBS (pH 7.2) 2.0 7.03
Water 50.0 175.86
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 284.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Abdelghany L, Kawabata T, Goto S, Jingu K, Li TS. Nicaraven induces programmed cell death by distinct mechanisms according to the expression levels of Bcl-2 and poly (ADP-ribose) glycohydrolase in cancer cells. Transl Oncol. 2022 Oct 4;26:101548. doi: 10.1016/j.tranon.2022.101548. Epub ahead of print. PMID: 36206675; PMCID: PMC9535466. 2. Komiya T, Higurashi K, Iizuka K, Mizuno Y. A novel free radical scavenger, nicaraven, inhibits human platelet aggregation in vitro. Clin Neuropharmacol. 1999 Jan-Feb;22(1):11-4. doi: 10.1097/00002826-199901000-00003. PMID: 10047928. 3. Ali H, Galal O, Urata Y, Goto S, Guo CY, Luo L, Abdelrahim E, Ono Y, Mostafa E, Li TS. The potential benefits of nicaraven to protect against radiation-induced injury in hematopoietic stem/progenitor cells with relative low dose exposures. Biochem Biophys Res Commun. 2014 Sep 26;452(3):548-53. doi: 10.1016/j.bbrc.2014.08.112. Epub 2014 Aug 28. PMID: 25173934. 4. Yokota R, Fukai M, Shimamura T, Suzuki T, Watanabe Y, Nagashima K, Kishida A, Furukawa H, Hayashi T, Todo S. A novel hydroxyl radical scavenger, nicaraven, protects the liver from warm ischemia and reperfusion injury. Surgery. 2000 Jun;127(6):661-9. doi: 10.1067/msy.2000.105864. PMID: 10840362.
In vitro protocol:
1. Abdelghany L, Kawabata T, Goto S, Jingu K, Li TS. Nicaraven induces programmed cell death by distinct mechanisms according to the expression levels of Bcl-2 and poly (ADP-ribose) glycohydrolase in cancer cells. Transl Oncol. 2022 Oct 4;26:101548. doi: 10.1016/j.tranon.2022.101548. Epub ahead of print. PMID: 36206675; PMCID: PMC9535466. 2. Komiya T, Higurashi K, Iizuka K, Mizuno Y. A novel free radical scavenger, nicaraven, inhibits human platelet aggregation in vitro. Clin Neuropharmacol. 1999 Jan-Feb;22(1):11-4. doi: 10.1097/00002826-199901000-00003. PMID: 10047928.
In vivo protocol:
1. Ali H, Galal O, Urata Y, Goto S, Guo CY, Luo L, Abdelrahim E, Ono Y, Mostafa E, Li TS. The potential benefits of nicaraven to protect against radiation-induced injury in hematopoietic stem/progenitor cells with relative low dose exposures. Biochem Biophys Res Commun. 2014 Sep 26;452(3):548-53. doi: 10.1016/j.bbrc.2014.08.112. Epub 2014 Aug 28. PMID: 25173934. 2. Yokota R, Fukai M, Shimamura T, Suzuki T, Watanabe Y, Nagashima K, Kishida A, Furukawa H, Hayashi T, Todo S. A novel hydroxyl radical scavenger, nicaraven, protects the liver from warm ischemia and reperfusion injury. Surgery. 2000 Jun;127(6):661-9. doi: 10.1067/msy.2000.105864. PMID: 10840362.
1: Ali H, Galal O, Urata Y, Goto S, Guo CY, Luo L, Abdelrahim E, Ono Y, Mostafa E, Li TS. The potential benefits of nicaraven to protect against radiation-induced injury in hematopoietic stem/progenitor cells with relative low dose exposures. Biochem Biophys Res Commun. 2014 Sep 26;452(3):548-53. doi: 10.1016/j.bbrc.2014.08.112. PubMed PMID: 25173934. 2: Kawakatsu M, Urata Y, Imai R, Goto S, Ono Y, Nishida N, Li TS. Nicaraven attenuates radiation-induced injury in hematopoietic stem/progenitor cells in mice. PLoS One. 2013;8(3):e60023. doi: 10.1371/journal.pone.0060023. PubMed PMID: 23555869; PubMed Central PMCID: PMC3612087. 3: Shimada Y, Tsunoda H, Zang L, Hirano M, Oka T, Tanaka T. Synergistic induction of heme oxygenase-1 by nicaraven after subarachnoid hemorrhage to prevent delayed cerebral vasospasm. Eur J Pharmacol. 2009 Oct 12;620(1-3):16-20. doi: 10.1016/j.ejphar.2009.08.009. PubMed PMID: 19686725. 4: Watanabe M, Akiyama N, Sekine H, Mori M, Manome Y. Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death. Anticancer Res. 2006 Sep-Oct;26(5A):3421-7. PubMed PMID: 17094462. 5: Katayama Y, Igarashi H. [Advances in the diagnosis and treatment of cerebral ischemia during the acute phase]. Rinsho Shinkeigaku. 2003 Nov;43(11):887-90. Review. Japanese. PubMed PMID: 15152494. 6: Yoshinaga H, Watanabe M, Manome Y. Possible role of nicaraven in neuroprotective effect on hippocampal slice culture. Can J Physiol Pharmacol. 2003 Jul;81(7):683-9. PubMed PMID: 12897815. 7: Leker RR. Nicaraven Chugai. Curr Opin Investig Drugs. 2003 Jan;4(1):83-90. Review. PubMed PMID: 12625035. 8: Naritomi H. [Neuroprotective therapy for the treatment of acute ischemic stroke]. Rinsho Shinkeigaku. 2001 Dec;41(12):1060-3. Review. Japanese. PubMed PMID: 12235795. 9: Longo M, Blandino A, Ascenti G, Ricciardi GK, Granata F, Vinci S. Cerebral angiography in the rat with mammographic equipment: a simple, cost-effective method for assessing vasospasm in experimental subarachnoid haemorrhage. Neuroradiology. 2002 Aug;44(8):689-94. PubMed PMID: 12185547. 10: Jain KK. Nicaraven for the treatment of cerebral vasospasm in subarachnoid haemorrhage. Expert Opin Investig Drugs. 2000 Apr;9(4):859-70. Review. PubMed PMID: 11060715. 11: Yokota R, Fukai M, Shimamura T, Suzuki T, Watanabe Y, Nagashima K, Kishida A, Furukawa H, Hayashi T, Todo S. A novel hydroxyl radical scavenger, nicaraven, protects the liver from warm ischemia and reperfusion injury. Surgery. 2000 Jun;127(6):661-9. PubMed PMID: 10840362. 12: Yamamoto S, Teng W, Nishizawa S, Kakiuchi T, Tsukada H. Improvement in cerebral blood flow and metabolism following subarachnoid hemorrhage in response to prophylactic administration of the hydroxyl radical scavenger, AVS, (+/-)-N,N'-propylenedinicotinamide: a positron emission tomography study in rats. J Neurosurg. 2000 Jun;92(6):1009-15. PubMed PMID: 10839263. 13: Akimoto T. Quantitative analysis of the kinetic constant of the reaction of N,N'-propylenedinicotinamide with the hydroxyl radical using dimethyl sulfoxide and deduction of its structure in chloroform. Chem Pharm Bull (Tokyo). 2000 Apr;48(4):467-76. PubMed PMID: 10783063. 14: Imperatore C, Germanò A, d'Avella D, Tomasello F, Costa G. Effects of the radical scavenger AVS on behavioral and BBB changes after experimental subarachnoid hemorrhage. Life Sci. 2000 Jan 21;66(9):779-90. PubMed PMID: 10698353. 15: Hasegawa M, Noda Y, Maeda Y, Yamada K, Nabeshima T. [The 1998 domestic state of development of cognitive enhancers]. Nihon Yakurigaku Zasshi. 1999 Dec;114(6):327-36. Japanese. PubMed PMID: 10672593. 16: Zingarelli B, Scott GS, Hake P, Salzman AL, Szabo C. Effects of nicaraven on nitric oxide-related pathways and in shock and inflammation. Shock. 2000 Feb;13(2):126-34. PubMed PMID: 10670842. 17: Hashimoto H, Ohta S, Utsunomiya H, Kumon Y, Sakaki S, Matsuda S, Sakanaka M. Changes in guanylate cyclase activity in arteriolar smooth muscle cells and hemodynamics after ischemia-reperfusion in rats. Acta Neuropathol. 1999 Dec;98(6):603-13. PubMed PMID: 10603036. 18: Komiya T, Higurashi K, Iizuka K, Mizuno Y. A novel free radical scavenger, nicaraven, inhibits human platelet aggregation in vitro. Clin Neuropharmacol. 1999 Jan-Feb;22(1):11-4. PubMed PMID: 10047928. 19: Masaki Y, Kumano K, Endo T, Iwamura M, Koshiba K, Yokota K, Okubo M. Protective effect of nicaraven against prolonged cold kidney preservation and reperfusion injury. Transplant Proc. 1998 Nov;30(7):3758-60. PubMed PMID: 9838646. 20: Yamanaka K, Kumura E, Yoshimine T, Maruno M, Taniguchi M, Kosaka H, Hayakawa T. Cellular expression of inducible nitric oxide synthase following rat cortical incision and its suppression by hydroxyl radical scavenger, 1,2-bis(nicotinamido)propane. Neurosci Res. 1998 Aug;31(4):347-50. PubMed PMID: 9809594.